¶ Alzheimer's Disease Calcium Homeostasis and Channel Modulator Companies
This category covers companies developing next-generation calcium homeostasis modulators for Alzheimer's disease beyond conventional L-type, T-type, and N-type calcium channel blockers. The calcium hypothesis of AD, first proposed by Khachaturian in 1989, posits that dysregulated intracellular calcium signaling is a central driver of neurodegeneration. While traditional calcium channel modulators target surface membrane channels, this field focuses on:
- Calcium-sensing receptor (CaSR) agonists and positive allosteric modulators
- Store-Operated Calcium Entry (SOCE) inhibitors targeting STIM1/ORAI1 axis
- Mitochondrial calcium uniporter (MCU) modulators
- Calmodulin inhibitors and modulators
- Calbindin/parvalbumin pathway enhancers
These targets address calcium dysregulation at the subcellular level, including endoplasmic reticulum calcium stores, mitochondrial calcium uptake, and nuclear calcium signaling.
The CaSR is a G protein-coupled receptor (GPCR) that monitors extracellular calcium levels and regulates cellular calcium homeostasis. In the brain, CaSR is expressed in neurons and glia, playing roles in:
- Synaptic plasticity: CaSR activation modulates NMDA receptor function and long-term potentiation
- Neuroprotection: CaSR agonists can reduce excitotoxicity and amyloid-beta toxicity
- Neuroinflammation: CaSR modulates microglial activation states
Targeting CaSR offers a mechanism distinct from voltage-gated calcium channels, with potential for allosteric modulation to achieve selectivity.
SOCE is the major pathway for calcium influx in non-excitable cells and operates in neurons through the STIM1 (stromal interaction molecule 1) and ORAI1 (orai calcium release-activated calcium modulator 1) proteins. Key features:
- ER calcium depletion triggers STIM1 oligomerization and ORAI1 activation
- Excessive SOCE is implicated in amyloid-beta-induced neuronal death
- STIM1/ORAI1 axis is upregulated in AD brains, contributing to calcium overload
SOCE inhibitors offer a targeted approach to normalize calcium influx without broadly suppressing neuronal activity.
The MCU complex is the primary pathway for mitochondrial calcium uptake. In AD:
- Calcium overload in mitochondria triggers permeability transition and cell death
- MCU dysfunction contributes to bioenergetic failure in neurons
- Selectivity is critical — global calcium blockade is toxic, but mitochondrial-specific targeting preserves normal neuronal function
Calmodulin is a calcium-binding messenger that transduces calcium signals into cellular responses. In AD:
- Calmodulin-dependent kinases phosphorylate tau at AD-relevant sites
- Calmodulin-regulated phosphodiesterases modulate cAMP signaling
- Calmodulin inhibitors may reduce tau pathology and improve synaptic function
¶ Parvalbumin and Calbindin
These calcium-buffering proteins regulate intracellular calcium dynamics. Loss of parvalbumin-positive interneurons is observed in AD, contributing to network hyperexcitability.
¶ Key Companies and Programs
- Headquarters: La Jolla, California, USA
- Founded: 2007
- Focus: CaSR antagonists for critical care and inflammatory diseases, with emerging CNS applications
- Technology: Novel CaSR modulators targeting allosteric sites
- Relevance: CaSR antagonism may reduce calcium dysregulation in AD neurons by modulating calcium set-point
- See: CalciMedica
- Headquarters: Cambridge, Massachusetts, USA / London, UK
- Founded: 2017
- Focus: NLRP3 inflammasome inhibitors; CaSR modulators for neuroinflammation
- Technology: CaSR is upstream of NLRP3 activation — modulating CaSR may reduce neuroinflammatory calcium signals
- Relevance: Addresses calcium dysregulation and neuroinflammation as interconnected AD pathways
- See: NodThera
- Headquarters: Seoul, South Korea
- Focus: CaSR-targeted therapeutics for neurodegeneration
- Lead Programs: KP-001, KP-002 — CaSR modulators in preclinical development for AD
- Technology: Allosteric CaSR modulators optimized for brain penetration
- Relevance: Addresses both neuronal calcium dysregulation and microglial activation
- Program: CM-02 series — SOCE inhibitors targeting STIM1/ORAI1 interaction
- Indication: ALS, Alzheimer's disease
- Stage: Preclinical
- Mechanism: Small molecule inhibitors of STIM1 oligomerization, blocking pathological SOCE without affecting basal calcium signaling
- Preclinical Data: CM-02 reduces amyloid-beta-induced calcium influx in primary neurons, with improved survival vs. vehicle
- See: CalciMedica
- Origin: University of Cambridge spinout
- Focus: ORAI1 channel inhibitors for neurodegeneration
- Technology: Structure-based design of selective ORAI1 blockers vs. ORAI2/ORAI3
- Stage: Discovery
- Relevance: ORAI1 inhibition reduces calcium overload while sparing essential calcium-dependent processes
- Headquarters: Rennes, France
- Focus: SOCE modulators for retinal and CNS disorders
- Technology: STIM1-targeting compounds with selectivity for pathological vs. physiological SOCE
- Relevance: Addresses neuronal calcium overload in AD while preserving synaptic function
- Headquarters: Boston, Massachusetts, USA
- Focus: Mitochondrial calcium uniporter (MCU) modulators
- Technology: Novel MCU blockers with selectivity for the mitochondrial pore vs. plasma membrane calcium channels
- Stage: Discovery
- Rationale: Blocking pathological mitochondrial calcium uptake prevents permeability transition pore opening and subsequent cell death
- Relevance: Addresses bioenergetic failure and cell death downstream of calcium overload in AD neurons
- Headquarters: Munich, Germany
- Focus: Mitochondrial calcium homeostasis for neurodegeneration
- Technology: Mitochondrial calcium-sensing molecules that regulate MCU activity based on cellular metabolic state
- Stage: Preclinical
- Relevance: Selectively blocks mitochondrial calcium uptake under pathological conditions (high cytosolic calcium, oxidative stress) while preserving normal mitochondrial calcium signaling
- Program: ACC-CAL series — calmodulin-dependent kinase (CaMK) inhibitors
- Indication: Alzheimer's disease, Parkinson's disease
- Stage: Discovery
- Technology: Structure-based design targeting CaMKII and CaMKIV, which are overactivated by amyloid-beta and promote tau phosphorylation
- Relevance: CaMKII inhibition reduces tau hyperphosphorylation while preserving synaptic plasticity
- Origin: Karolinska Institutet spinout
- Focus: Calmodulin-regulated phosphodiesterase 1 (PDE1) inhibitors
- Technology: PDE1 inhibitors restore cAMP signaling disrupted by excessive calmodulin activity
- Stage: Lead optimization
- Relevance: PDE1 is activated by calcium/calmodulin; inhibition may improve synaptic function and memory in AD
- Focus: Parvalbumin replacement and enhancement strategies
- Technology: Peptide mimetics of parvalbumin calcium-binding domains
- Stage: Discovery
- Relevance: Restoring parvalbumin in fast-spiking interneurons may normalize inhibitory tone and reduce network hyperexcitability in AD
¶ L-Type and N-Type Calcium Channel Modulators (Specialized AD Focus)
¶ Vanderbilt University / NIH Blueprint Program
- Institution: Vanderbilt University Medical Center
- Focus: Development of selective N-type (Cav2.2) calcium channel blockers with enhanced brain penetration for AD
- Technology: Peptide toxins and small molecules targeting Cav2.2 over Cav1.x channels
- Stage: Preclinical
- Relevance: N-type channel blockade reduces excitatory neurotransmitter release and protects against excitotoxicity
- Program: Previous research on L-type calcium channel blockers (nimodipine, isradipine) for AD showed limited efficacy
- Current Focus: Repositioning to Cav1.3-selective modulators (to avoid cardiovascular effects of broad L-type blockade) and R-type (Cav2.3) calcium channels
- Technology: Subtype-selective compounds with improved selectivity profiles
- Stage: Discovery
- Note: Earlier clinical trials with non-selective L-type blockers were largely negative, but Cav1.3 selectivity may improve the risk/benefit ratio
- See: Merck
| Company |
Mechanism |
Target |
AD Program |
Stage |
| CalciMedica |
SOCE inhibitor |
STIM1/ORAI1 |
CM-02 |
Preclinical |
| CalciMedica |
CaSR modulator |
Calcium-sensing receptor |
CM series |
Discovery |
| NodThera |
CaSR/NLRP3 |
Allosteric modulator |
NT series |
Discovery |
| Accerise |
CaMK inhibitor |
CaMKII/IV |
ACC-CAL |
Discovery |
| BioKyra |
PDE1 inhibitor |
Calmodulin pathway |
BK series |
Lead opt. |
| Khlorum |
MCU blocker |
Mitochondrial Ca2+ uptake |
KH series |
Discovery |
| SynapseDx |
PV mimetic |
Parvalbumin replacement |
SY series |
Discovery |
| Kal Pharmaceuticals |
CaSR PAM |
Calcium-sensing receptor |
KP-001, KP-002 |
Preclinical |
| Vanderbilt/NIH |
N-type blocker |
Cav2.2 |
Research program |
Preclinical |
¶ Therapeutic Rationale and Clinical Strategy
Calcium dysregulation is one of the earliest and most consistent features of AD, preceding amyloid and tau pathology. The calcium hypothesis posits that:
- Aging causes gradual impairment of calcium regulatory systems
- Amyloid-beta amplifies calcium dysregulation through channel formation and receptor modulation
- Tau pathology disrupts calcium homeostasis via dendritic spine loss and mitochondrial dysfunction
- Excessive intracellular calcium activates destructive enzymatic pathways (calpains, caspases, kinases) and leads to mitochondrial failure
Compared to traditional L-type/T-type channel blockers, subcellular calcium modulators offer:
- Selectivity: Target only pathological calcium signals, preserving normal synaptic function
- Disease-modifying potential: Address upstream calcium dysregulation rather than downstream symptoms
- Combination potential: Complement amyloid/tau-targeting therapies without mechanism conflict
- Biomarkers: Calcium imaging (GCaMP fiber photometry), mitochondrial calcium sensors (mitPerCP), synaptic markers
- Genetic stratification: CACNA1C (L-type), CALM1/CALM2 (calmodulin), STIM1/ORAI1 variants may inform patient selection
- Imaging endpoints: PET calcium reporters under development for human use
- Combination: Pairing calcium homeostasis modulators with anti-amyloid or anti-tau therapies may enhance disease modification